Key result
Clopidogrel inhibits ADP-induced tyrosine phosphorylation alongside platelet aggregation in rat platelets.
Why the study?
The effect of clopidogrel on ADP-induced phosphorylations in platelets and its relation to platelet aggregation and shape change was investigated.
Clopidogrel selectively inhibits tyrosine phosphorylations coupled to low-affinity ADP receptors involved in platelet aggregation, without affecting phosphorylations linked to high-affinity receptors mediating shape change.
No takes yet. Share an insight, caveat, or question.
May guide ADP antagonist development in platelet signaling; leaves open translation to human clinical outcomes.
Savi et al. (1997) studied this question. Clopidogrel was evaluated on ADP-induced phosphorylations. Clopidogrel treatment in rat platelets inhibited the increase in tyrosine phosphorylation of several proteins concomitantly with the inhibition of platelet aggregation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: